Characterization of Caenorhabditis elegans homologs of the Down syndrome candidate gene DYRK1A

被引:0
|
作者
Raich, WB
Moorman, C
Lacefield, CO
Lehrer, J
Bartsch, D
Plasterk, RHA
Kandel, ER
Hobert, O
机构
[1] Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, Dept Biochem & Mol Biophys, New York, NY 10032 USA
[2] Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA
[3] Hubrecht Lab, NL-3584 CT Utrecht, Netherlands
关键词
D O I
暂无
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The pathology of trisomy 21/Down syndrome includes cognitive and memory deficits. Increased expression of the dual-specificity protein kinase DYRK1A kinase (DYRK1A) appears to play a significant role in the neuropathology of Down syndrome. To shed light on the cellular role of DYRK1A and related genes we identified three DYPLK/minibrain-like genes in the genome sequence of Caenorhabditis elegans, termed mbk-1, mbk-2, and hpk-1. We found these genes to be widely expressed and to localize to distinct subcellular compartments. We isolated deletion alleles in all three genes and show that loss of mbk-1, the gene most closely related to DYRK1A, causes no obvious defects, while another gene, mbk-2, is essential for viability. The overexpression of DYRK1A in Down syndrome led us to examine the effects of overexpression of its C. elegans ortholog mbk-1. We found that animals containing additional copies of the mbk-1 gene display behavioral defects in chemotaxis toward volatile chemoattractants and that the extent of these defects correlates,with mbk-1 gene dosage. Using tissue-specific and inducible promoters, we show that additional copies of mbk-1 can impair olfaction cell-autonomously in mature, fully differentiated neurons and that this impairment is reversible. Our results suggest that increased gene dosage of human DYRK1A in trisomy 21 may disrupt the function of fully differentiated neurons and that this disruption is reversible.
引用
收藏
页码:571 / 580
页数:10
相关论文
共 50 条
  • [31] Leucettinib-21, a DYRK1A Kinase Inhibitor as Clinical Drug Candidate for Alzheimer's Disease and Down Syndrome
    Meijer, Laurent
    Chretien, Emilie
    Ravel, Denis
    JOURNAL OF ALZHEIMERS DISEASE, 2024, 101 : S95 - S113
  • [32] Skeletal health in DYRK1A syndrome
    Otte, Elysabeth D.
    Roper, Randall J.
    FRONTIERS IN NEUROSCIENCE, 2024, 18
  • [33] DYRK1A Is a Therapeutic Target in B-ALL in Children with Down Syndrome
    Lee, Paul
    Bhansali, Rahul
    Rammohan, Malini
    Hijiya, Nobuko
    Izraeli, Shai
    Bourquin, Jean-Pierre
    Malinge, Sebastien
    Crispino, John
    BLOOD, 2016, 128 (22)
  • [34] Attenuation of Notch signalling by the Down-syndrome-associated kinase DYRK1A
    Fernandez-Martinez, Javier
    Vela, Eva M.
    Tora-Ponsioen, Mireille
    Ocana, Oscar H.
    Angela Nieto, M.
    Galceran, Juan
    JOURNAL OF CELL SCIENCE, 2009, 122 (10) : 1574 - 1583
  • [35] The MNB/DYRK1A protein kinase:: neurobiological functions and Down syndrome implications
    Hämmerle, B
    Elizalde, C
    Galceran, J
    Becker, W
    Tejedor, FJ
    JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, 2003, (67): : 129 - 137
  • [36] Triplication of DYRK1A causes retinal structural and functional alterations in Down syndrome
    Laguna, Ariadna
    Barallobre, Maria-Jose
    Marchena, Miguel-Angel
    Mateus, Catarina
    Ramirez, Erika
    Martinez-Cue, Carmen
    Delabar, Jean M.
    Castelo-Branco, Miguel
    de la Villa, Pedro
    Arbones, Maria L.
    HUMAN MOLECULAR GENETICS, 2013, 22 (14) : 2775 - 2784
  • [37] Dyrk1a from Gene Function in Development and Physiology to Dosage Correction across Life Span in Down Syndrome
    Atas-Ozcan, Helin
    Brault, Veronique
    Duchon, Arnaud
    Herault, Yann
    GENES, 2021, 12 (11)
  • [38] Expression patterns and subcellular localization of the Down syndrome candidate protein MNB/DYRK1A suggest a role in late neuronal differentiation
    Hämmerle, B
    Carnicero, A
    Elizalde, C
    Ceron, J
    Martínez, S
    Tejedor, FJ
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2003, 17 (11) : 2277 - 2286
  • [39] DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome
    Duchon, Arnaud
    Herault, Yann
    FRONTIERS IN BEHAVIORAL NEUROSCIENCE, 2016, 10
  • [40] DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down Syndrome
    Feki, Anis
    Hibaoui, Youssef
    BRAIN SCIENCES, 2018, 8 (10):